Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

Pfizer (PFE) closed the most recent trading day at $26.50, moving +2.4% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. At the same time, the Dow lost 0.83%, and the tech-heavy Nasdaq gained 0.91%. Prior to today's trading, shares of the drugmaker had gained 3.52% outpaced the Medical sector's loss of 0.74% and the S&P 500's gain of 0.38%.The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its earnings on February 3, 2026. The company's upcoming EPS is projected at $0.57, signifying a 9.52% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $16.93 billion, reflecting a 4.68% fall from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.13 per share and revenue of $61.96 billion, indicating changes of +0.64% and 0%, respectively, compared to the previous year. Investors should also take note of any recent adjustments to analyst estimates for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. At present, Pfizer boasts a Zacks Rank of #5 (Strong Sell). From a valuation perspective, Pfizer is currently exchanging hands at a Forward P/E ratio of 8.66. This expresses a discount compared to the average Forward P/E of 15.48 of its industry. The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 199, this industry ranks in the bottom 19% of all industries, numbering over 250. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Just Released: Zacks Top 10 Stocks for 2026Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks